The text starts here.

News Release

FOR IMMEDIATE RELEASE
December 15, 1997

Eisai Launches PARIET (sodium rabeprazole), A New Proton Pump Inhibitor for Peptic Ulcers in Japan

December 15, 1997 - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced the December 16 launch of PARIET (sodium rabeprazole), a new proton pump inhibitor for peptic ulcers including gastric ulcer and duodenal ulcer in Japan.


PARIET is classified as a proton pump inhibitor, and was synthesized by Eisai in Japan. The compound is being developed by Eisai in Japan,Europe and the US. PARIET demonstrates strong proton pump inhibition at the final stage of acid secretion by preventing the function of the enzyme responsible for stomach acid production.


Clinically, PARIET demonstrates efficacy in relief of stomach pain and healing for gastric ulcer, duodenal ulcer, anastomach ulcer and gastroesophageal reflux disease. PARIET is usually dosed at 10 mg daily and a 20 mg daily dose is available for recurrent and severe ulcers depending on the patient's symptoms.


Eisai submitted an application for marketing to the UK Medicines Control Agency (MCA) in January 1997 and plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in 1998. PARIET is one of Eisai's global strategic products following ARICEPT, a new drug for the symptomatic treatment of mild to moderate Alzheimer's disease.


Peptic ulcers including gastric ulcers and duodenal ulcers are among the most common diseases in the world. The market size is estimated to be approximately yen200 billion in Japan, yen600 billion in the US and yen400 billion in Europe.


Eisai expects sales of yen3 billion for PARIET in Japan for the fiscal year ending in March 1998.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of $2.3 billion in 1996 with approximately 14 percent of sales spent for research and development.